Ulcerative Colitis

Small molecule therapies offer patients with mild or moderate inflammatory bowel disease a much cheaper alternative to biologics.

A diet that is high in sugar, fried foods, and lacks vegetables increases the risk of pediatric inflammatory bowel disease.

Expert gastroenterologists delve into the long-term management of Crohn’s disease and ulcerative colitis and examine the latest treatment options and strategies to enhance patient outcomes.

There remains a need for more biosimilars in gastroenterology.

Patients in long-remission also presented with fecal bacterial composition that was similar to what was found in the healthy control group and there was a positive correlation between Akkermansia muciniphila abundance and time in remission.

Disease activity and treatment with a small-molecule or an investigation drug were independently linked to an exclusion diet, while a history of stenosis and active disease were associated with fasting.

The results show 52.5% of patients achieved clinical remission at week 96, while 59.0% saw endoscopic improvement, 35.9% achieved endoscopic remission, and 70.5% achieved a clinical response.

There are many reasons why biosimilars are not utilized in gastroenterology, mainly patients present younger and treatments can lose efficacy over time.

Some traditional sarcopenia assessment techniques included direct measurements on cross sectional imaging, but cross sectional imaging also comes with increased time, cost, and radiation exposure.

Using the bidirectional Montreal classification system, which accounts for disease regression, showed that 90% of patients exhibited inflammatory disease behavior at 5 years, compared to 58% if the hierarchical, unidirectional Montreal classification system was implemented.

The FDA cited manufacturing concerns in their letter for the potential ulcerative colitis treatment.

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

At the 6 month follow-up visit, all participants had stable folic acid levels without macrocytic anemia and the monthly questionnaires showed no increase in symptoms or adverse events reported.

Patients at a risk of malnutrition had a significantly lower mean of albumin, as well as significantly increased proportion of patients with CRP >5 mg/L.

The results show 83% of patients in the combination group achieved clinical response at week 12, compared to 61% of the golimumab monotherapy group and 75% of the guselkumab group.

The 2 groups had similar data for any endoscopic recurrence and severe endoscopic recurrence at the first endoscopic evaluation.

Acute severe ulcerative colitis and a greater number of biologics precoloectomy were linked to an increased probability of acute pouchitis, while older age at colectomy was associated with a decreased probability of acute pouchitis.

The results from the INSPIRE trial show risankizumab met all primary and secondary endpoints in treating adult patients with moderately to severely active ulcerative colitis.

Clinical remission and clinical response odds, in both induction and maintenance periods, have been consistent over time.

In the infliximab reference group, the persistence at month 12 was 94% for Crohn’s disease and 92.8% for ulcerative colitis.

The results show concomitant recurrent CDI was associated with an IBD flare in 54% of participants. Of this group, 63% received IBD remission-induction therapy before FMT.

Recent data during ECCO 23 show ustekinumab results in higher rates of clinical remission and clinical response in patients with inflammatory bowel disease.

There was a 0.9% increase in the first dispensation of infliximab, either the biosimilar or originator during the first year of follow-up, as well as a 16.2% increase in infliximab dose escalation, a 2.4% decrease in the dispensation of antibiotics, and a 2.6% decrease in the new use of prednisone.

The patients that did not undergo colectomy in the infliximab group were more often re-hospitalized because to the need for intravenous corticosteroids at the two-year follow-up compared to the cyclosporine group.

Individuals that did not respond had a lower percentage of naïve T cells compared to responders, while responders had a lower percentage of Th2 and CD4 central memory subsets before vaccination.